Observed and relative survival after aortic valve replacement  by Kvidal, Per et al.
Observed and Relative Survival
After Aortic Valve Replacement
Per Kvidal, MD,* Prof. Reinhold Bergstro¨m, PHD,‡ Lars-Gunnar Ho¨rte, PM, BA,§
Elisabeth Ståhle, MD, PHD†
Uppsala and Stockholm, Sweden
OBJECTIVES We sought to evaluate the effects of a number of factors that can potentially determine the
optimal time for aortic valve replacement (AVR) and the observed and relative survival after
the operation.
BACKGROUND Aortic valve replacement is performed in patients within a wide age span, but the proportion
of elderly patients is increasing. In survival analyses, adjustment for the effects of age is
therefore essential. Analysis of relative survival provides additional information on excess or
disease-specific mortality and its risk factors.
METHODS Survival was analyzed in 2,359 patients (1,442 without and 917 with concomitant coronary
artery bypass graft surgery) undergoing their first AVR. By relating observed survival to that
expected among the general Swedish population stratified by age, gender and five-year
calendar period, the relative survival and disease-specific survival were estimated.
RESULTS Early mortality after AVR (death within 30 days) was 5.6%. Relative survival rates (excluding
early deaths) after 5, 10 and 15 years were 94.6%, 84.7% and 74.9%, respectively. There was
an excess risk of dying during the entire follow-up period. Advanced New York Heart
Association functional class, preoperative atrial fibrillation and pure aortic regurgitation were
independent risk factors for observed and relative survival. Patients in the oldest age group
showed decreased observed survival but excellent relative survival.
CONCLUSIONS Old age was not a risk factor for excess mortality after AVR, whereas atrial fibrillation
decreased relative survival substantially. (J Am Coll Cardiol 2000;35:747–56) © 2000 by the
American College of Cardiology
Aortic valve replacement (AVR) is performed in patients
within a wide age range. During recent years the average age
of the entire patient population has increased as a result of
a higher proportion of elderly patients (1).
In the present study we investigated the impact of risk
factors on relative survival after AVR. Calculation of relative
survival is one way of measuring excess mortality among
patients who have had heart valve replacement in relation to
the mortality in the general population. Thus, relative
survival and the effects on it by factors related to different
aspects of the status of native aortic valve disease at the time
of operation provide additional information on patient
outcome after heart valve surgery that may be useful when
considering the optimal time for surgical repair in the
individual patient.
In this study relative survival was estimated in all patients
who underwent AVR in Uppsala, Sweden, during a 15-year
period. To obtain the relative survival in our study group of
2,359 patients, we compared the survival rate in these
patients with that in the total Swedish population, adjusted
for gender, age and five-year calendar period.
METHODS
Patients. From January 1980 through December 1995,
2,359 patients underwent primary AVR, with (n 5 917) or
without (n 5 1,442) concomitant coronary artery bypass
graft surgery (CABG) at the Department of Thoracic and
Cardiovascular Surgery of the University Hospital, Uppsala,
Sweden.
There were 1,499 men (64%; mean age 63.2 years, range
18 to 88) and 860 women (36%; mean age 67.4 years, range
21 to 86). Preoperative coronary angiography was per-
formed in all patients $50 years old and in all patients with
angina or in whom coronary artery disease was suspected on
a clinical basis.
All operations were carried out using a standard tech-
From the *Department of Cardiology and †Department of Thoracic and Cardio-
vascular Surgery, University Hospital, Uppsala; ‡Department of Statistics, University
of Uppsala, Uppsala; and §Department of Public Health Sciences, Karolinska
Institute, Stockholm, Sweden. Financial support was provided by the Swedish
National Association against Heart and Lung Disease and the Uppsala County
Association Against Heart and Lung Disease.
Manuscript received April 22, 1999; revised manuscript received September 20,
1999, accepted November 3, 1999.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00584-7
nique for cardiopulmonary bypass and moderate hypother-
mia (25 to 32°C).
Our current policy is to recommend a bioprosthesis to
patients $70 years old. However, the type and trademark of
the prosthesis were left to the discretion of each surgeon. Of
the 2,359 patients, 1,776 received a mechanical valve (St.
Jude, n 5 575; Bjo¨rk-Shiley, n 5 625; Duromedics, n 5
199; Carbomedic, n 5 299; composite graft, n 5 20; and
other unspecified, n 5 58) and 583 patients received a
bioprosthesis (Carpentier-Edwards, n 5 213; Sorin, n 5
196; St. Jude, n 5 32; and miscellaneous types, n 5 142).
Seven patients underwent concomitant mitral annuloplasty.
Patients with a mechanical valve were prescribed life-long
treatment, whereas most patients with a bioprosthesis were
recommended three months of anticoagulation, unless atrial
fibrillation (AF) or other conditions indicated a high risk of
thromboembolism. The therapeutic level of prothrombin
complex (factors II, VII and X) ranged from 10% to 25%,
corresponding to an international normalized ratio (INR) of
2.1 to 4.3.
Data collection, follow-up and outcome events. All clin-
ical data were recorded prospectively and stored in a
computer. New York Heart Association (NYHA) func-
tional classification (2) of congestive heart failure was made
on the basis of the preoperative interview with the patient.
Patients who had slight discomfort in their normal activities
but were able to walk a mile at their own speed and could
climb stairs slowly without undue discomfort were allocated
to functional class IIIA. Patients who could manage only
the lightest activity without discomfort, those who were able
to walk only short distances without resting and those who
had difficulty climbing stairs were allocated to functional
class IIIB.
A unique 10-digit national registration number is allo-
cated to every Swedish citizen. In January 1996, all patients
were followed up with respect to survival by computerized
linkage to two national registers—namely, the Swedish
Cause of Death Register and a continuously updated pop-
ulation register. By use of these combined registers, all
patients could be assigned a date of death or identified as
being alive on December 31, 1995. The mean follow-up
period was 71.5 months.
Statistical methods. EARLY MORTALITY (DEATH FROM ANY
CAUSE WITHIN 30 DAYS POSTOPERATIVELY). For identifica-
tion of factors related to early outcome, logistic regression
analysis was performed (3). The odds ratio (OR) from this
analysis was used as a measure of the relative risk.
LONG-TERM SURVIVAL (DEATH FROM ANY CAUSE AFTER 30
DAYS POSTOPERATIVELY). The observed survival rate for all
causes of death was calculated by the actuarial (life-table)
method.
The following variables were entered into the Cox anal-
yses of observed survival: demographic variables (age at
operation, gender, year of surgery), disease history (previous
myocardial infarction), symptoms and clinical status (dys-
pnea, left heart failure, NYHA functional class, preoperative
heart rhythm [sinus rhythm, AF or other]), associated
conditions (hypertension, diabetes, other serious diseases
[e.g., malignancies]), preoperative catheterization data
(presence of significant coronary artery disease [i.e., $50%
stenosis in at least one coronary artery], type of lesion [pure
aortic regurgitation, aortic stenosis or combined lesion]) and
characteristics of the surgical procedure (concomitant
CABG, mechanical vs. biologic prosthesis).
Age as a variable was used both as a linear continuous
variable and in categorized form. There was little difference
between the explanatory power of the two alternatives (log
rank statistics: 124.17 with 1 df for age in continuous form
and 117.46 with 3 df for variables categorized into four
10-year intervals as shown in Table 1). In the age-adjusted
models, the difference between the estimates of the effects of
the other variables was small enough to be of no conse-
quence. Thus, age can be used in either categorized or
continuous form, depending on which alternative is more
suitable in a certain situation.
The relative survival rate was computed as the ratio of the
observed to the expected survival rate (4,5). The expected
survival rates were calculated from life-tables compiled from
the total population of Sweden stratified by gender, five-
year age group and five-year calendar period (6). The ratio
O/E—where O 5 observed number of deaths and E 5
expected number of deaths in a cohort in the general
population similar to the study cohort of patients with
respect to gender, age and intervention period—was also
calculated. The reference cohort in the general population
was updated annually, with correction for withdrawals.
Univariate and multivariate analyses of relative survival were
performed for the factors that gave independent information
on observed survival in the multivariate Cox model. The
multivariate analyses were based on a multiplicative model,
where the ratio O/E (or corresponding death risk) was
assumed to depend on the explanatory variables of age,
NYHA functional class, concomitant CABG, AF, aortic
regurgitation and follow-up year. The model was estimated
by the maximal likelihood method on the assumption that
the observed number of deaths had a Poisson distribution
(7). Multivariate analysis of relative survival was based on
Abbreviations and Acronyms
AF 5 atrial fibrillation
AVR 5 aortic valve replacement
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
NYHA 5 New York Heart Association
OR 5 odds ratio
RH 5 relative hazard
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grouped data, with the explanatory variables categorized as
in Table 1. In addition, follow-up time was included, with
15 categories (years 1 through 15).
RESULTS
Early mortality. One hundred and thirty-two patients
(5.6%) died within the first postoperative month. In patients
undergoing AVR, the following factors influenced early
mortality independently: advanced NYHA functional class
(IIIB: OR 1.63, 95% confidence interval [CI] 1.10 to 2.39;
class IV: OR 4.26, 95% CI 2.35 to 7.73), preoperative AF
(OR 1.74, 95% CI 1.07 to 2.80) and older age ($70 years:
OR 1.45, 95% CI 1.01 to 2.09).
Long-term survival. All analyses of long-term survival
were based on the 2,227 patients who were alive after one
month. Observed and relative survival is depicted in Figure
1. The observed survival rates after 5, 10 and 15 years were
82.9%, 63.4% and 46.2%, respectively. The corresponding
figures for relative survival were 94.6%, 84.7% and 74.9%.
The observed death risk during the first year postopera-
Table 1. Association Between Explanatory Variables and Age in Patients Who Survived the First Postoperative Month After AVR
Age (yrs) n <50 51–60 61–70 >71
Mean 6 SD
(yrs)
NYHA functional class
I/II 283 32.0% 15.9% 10.2% 6.6% 56.8 6 14.7
IIIA 958 40.3% 47.8% 47.8% 36.1% 64.2 6 10.9
IIIB/IV 986 27.7% 36.3% 42.1% 57.3% 67.2 6 10.7
Type of valve lesion
AVS/combination* 1,755 48.2% 67.9% 81.6% 92.9% 66.8 6 10.3
Regurgitation 472 51.8% 32.1% 18.4% 7.1% 56.4 6 13.5
Concomitant CABG
No 1,372 92.8% 69.8% 58.8% 48.8% 61.8 6 13.0
Yes 855 7.2% 30.2% 41.2% 51.2% 69.0 6 7.8
AF
No 2,016 97.5% 92.8% 88.6% 88.9% 64.2 6 12.1
Yes 211 2.5% 7.2% 11.4% 11.1% 68.5 6 8.5
*Aortic valve stenosis or combined stenotic and regurgitant lesion.
AF 5 atrial fibrillation; CABG 5 coronary artery bypass grafting; NYHA 5 New York Heart Association.
Table 2. Results of Univariate and Multivariate Analyses Based on Observed Late (Deaths Within 30 Days of Aortic Valve
Replacement Excluded) Survival Using the Cox Regression Model
n
Univariate Age-Adjusted Multivariate
RH 95% CI RH 95% CI RH 95% CI
NYHA functional class
I/II 283 1.0 Reference 1.0 Reference 1.0 Reference
IIIA 958 2.2 1.6–3.2 1.7 1.2–2.5 1.7 1.2–2.4
IIIB/IV 986 3.2 2.2–4.4 2.2 1.6–3.2 2.1 1.5–3.0
Valve lesion
Type of AVS/combination* 1,755 1.0 Reference 1.0 Reference 1.0 Reference
Regurgitation 472 1.0 0.8–1.2 1.5 1.3–1.9 1.6 1.3–1.9
Concomitant CABG
No 1,372 1.0 Reference 1.0 Reference 1.0 Reference
Yes 855 1.6 1.3–1.8 1.3 1.1–1.5 1.3 1.1–1.5
AF
No 2,016 1.0 Reference 1.0 Reference 1.0 Reference
Yes 211 2.3 1.9–2.9 2.1 1.7–2.1 2.1 1.7–2.6
Age (yrs)
#50 277 1.0 Reference — — 1.0 Reference
51–60 380 2.4 1.6–3.6 — — 2.2 1.5–3.4
61–70 841 3.9 2.7–5.6 — — 3.5 2.4–5.1
$71 729 5.2 3.5–7.6 — — 5.6 3.0–6.8
*Aortic valve stenosis or combined stenotic and regurgitant lesion.
AF 5 atrial fibrillation; CABG 5 coronary artery bypass graft surgery; CI 5 confidence interval; NYHA 5 New York Heart Association; Reference 5 reference category;
RH 5 relative hazard.
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tively was 0.044 (Fig. 2). The risk was at a minimum during
the third and fourth years and then increased. During the
last few years of follow-up, there were too few events for
accurate estimation.
The expected death risk was 0.023 during the first year
and gradually increased with increasing follow-up time (Fig.
2). During the tenth year it was 0.034. This meant that in
the study cohort there was an excess risk of dying during
each of the first 12 years of follow-up.
Explanatory variables. There was a very strong association
between age and the other explanatory variables (NYHA
functional class, aortic regurgitation, concomitant CABG,
and AF) (Table 1). During the study period, the proportion
of elderly patients increased (17% of the patients undergo-
ing AVR during the period 1980 through 1985 were $71
years old, compared with 34% during the period 1986
through 1990 and 47% during the period 1991 through
1995). The proportion of patients who underwent concom-
itant CABG also increased, from 24% during the earlier
time period to 44% during the period 1991 through 1995.
The distribution of the other explanatory variables was
virtually unchanged during the study period.
Observed survival. The results of univariate analyses by
the Cox proportional hazards model are given in Table 2.
After adjustment for age, the previous insignificant effect of
aortic regurgitation became significant (Table 2).
Figure 1. Observed (open circles) and relative (solid circles) survival after primary AVR in patients who survived the first postoperative
month (n 5 2,227). The figure shows 95% confidence intervals at 5, 10 and 15 years and the numbers (N) of patients at risk. Early deaths
(within 30 days) are also given.
Figure 2. The annual observed (solid diamonds) and expected (open diamonds) death risk after primary AVR in patients who survived
the first postoperative month (n 5 2,227). The numbers (N) of patients at risk and the first year death risk are given.
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The full multivariate model produced results that were
very close to those obtained with adjustment for age only.
All five variables included in the model became strongly
significant (Table 2).
Analyses were performed on two different follow-up
periods—0 to 5 years and .5 years (Table 3)—and the
effects of the risk factors were allowed to change between
the intervals. The effects of aortic regurgitation, concomi-
tant CABG and AF still persisted after five years of
follow-up, and in some cases even strengthened. The
effect of NYHA functional class decreased markedly, with
relative hazards of 1.44 and 1.56 after more than five
years, compared with 2.03 and 2.75 during the first five
years.
Relative survival. Figures 3 through 7 show the relative
survival in relation to different categories of the explanatory
variables. Patients in NYHA functional class II (Fig. 3) had
a relative survival .100% for basically the entire follow-up
period (i.e., survival was better than of the corresponding
group in the general population cohort). Patients in func-
tional class IIIB or IV had an excess mortality rate of 20%
and 32% 10 and 15 years, respectively, after AVR.
Age was the exceptional variable, for which the relative
Figure 3. Relative survival after primary AVR by preoperative NYHA functional class in patients who survived the first postoperative
month. The numbers (N) of patients at risk and the number of deaths within 30 days in each group are given.
Table 3. Comparison of Relative Hazards at Different Time Intervals in Survivors After AVR, Based on Analyses of Observed
Survival Using a Modified Cox Regression Model
0 to 5 Years After Operation >5 Years After Operation
n Deaths RH 95% CI n Deaths RH 95% CI
Total 2,227 331 — — 1,204 287 — —
NYHA functional class
I/II 283 14 1.0 Reference 159 22 1.0 Reference
IIIA 958 123 2.0 1.2–3.6 517 118 1.4 0.9–2.3
IIIB/IV 986 194 2.8 1.6–4.8 528 147 1.6 1.0–2.5
Type of valve lesion
AVS/combination* 1,755 256 1.0 Reference 939 218 1.0 Reference
Regurgitation 472 75 1.7 1.3–2.2 265 69 1.5 1.1–2.0
Concomitant CABG
No 1,372 177 1.0 Reference 804 179 1.0 Reference
Yes 855 154 1.2 1.0–1.5 400 108 1.3 1.0–1.7
AF
No 2,016 272 1.0 Reference 1,117 248 1.0 Reference
Yes 211 59 1.9 1.4–2.6 87 39 2.2 1.6–3.1
Age (yrs)
Continuous 1.0 1.0–1.1 1.1 1.0–1.1
*Aortic valve stenosis or combined stenotic and regurgitant lesion. Abbreviations as in Table 2.
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survival analyses yielded quite different results from those
based on observed survival (Fig. 4, Table 1). The oldest age
group had a relative survival .100% for a large part of the
follow-up period.
Observed and expected death risks. When considering
basic descriptive data on the observed and expected numbers
of deaths (Table 4), we found that in the youngest age group
the O/E ratio was 4.5 (31 observed deaths compared with
6.8 expected ones) whereas in the oldest age group there
were almost the same numbers of observed (n 5 212) and
expected deaths (n 5 208.2), with an O/E ratio of 1.02.
The full multivariate model is shown in Table 5. The age
effect was strongly negative, with a relative risk of 0.21 for
the oldest age group compared with the youngest age group.
For the other explanatory variables, the difference between
analyses based on observed survival, with adjustment for age
and relative survival, was limited. The relative hazard (RH)
associated with concomitant CABG was now so small that
it was not significant at the 5% level (p 5 0.095, RH 1.15,
95% CI 0.98 to 1.36).
DISCUSSION
This study was a prospective study of a substantial
number of consecutive patients (n 5 2,359) who under-
Figure 4. Relative survival after primary AVR by age at operation in patients who survived the first postoperative month. The numbers
(N) of patients at risk and the number of deaths within 30 days in each group are given.
Figure 5. Relative survival after primary AVR in patients with and without concomitant CABG who survived the first postoperative
month. The numbers (N) of patients at risk and the number of deaths within 30 days in each group are given.
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went AVR. The numbers of patients within the different
subgroups were adequate for valid generalization of the
results to patients with the characteristics in question.
With a mean follow-up time of 6 years, corresponding to
14,046 patient-years, the present study has given us one
of the most comprehensive analyses of survival after
AVR.
In this study we used as our control the “expected”
survival of the Swedish population. The survival rates of the
total patient group did not return to the normal expected
survival of their age- and gender-matched cohort in the
general population. The study results underline the pallia-
tive rather than curative potential of heart valve replacement
in most patient groups (1,8–11).
Factors that influence survival after AVR. The presence
of AF preoperatively reduced the observed and relative
survival substantially in patients with an aortic lesion.
Among patients who underwent AVR and had preoperative
AF, 40% were alive after 10 years, corresponding to an
excess mortality rate of 42%. After 15 years, only 18% of the
patients were alive, corresponding to an excess mortality rate
Figure 6. Relative survival after primary AVR by type of lesion in patients who survived the first postoperative month. The numbers (N)
of patients at risk and the number of deaths within 30 days in each group are given.
Figure 7. Relative survival after primary AVR by preoperative heart rhythm in patients who survived the first postoperative month. The
numbers (N) of patients at risk and the number of deaths within 30 days in each group are given.
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of 67%. Atrial fibrillation is a known independent risk factor
for deaths after AVR (12). This might be attributed to more
advanced myocardial dysfunction, to an associated increased
risk of lethal thromboembolism or to the occurrence of
major hemorrhages in patients with biologic valve substi-
tutes who otherwise would not be anticoagulated. However,
AF may also imply a compromised hemodynamic situation
and disturbed heart rate regulation during both rest and
physical stress (13). This may counteract the recovery of the
left ventricular morphology as well as geometry after the
operation, thereby accelerating the development of heart
failure (14,15).
This study also confirms previous findings of increased
excess mortality among patients with aortic regurgitation
(10–12). These patients are younger than patients with
isolated aortic stenosis or mixed valve disease. Both the
etiology and clinical characteristics in this type of lesion
differ from those in pure stenosis or the combined lesion.
Patients with concomitant CABG showed decreased
observed long-term survival. However, these patients were
older at the time of operation. Consequently, age adjust-
ment reduced the effect on observed survival, and there was
no significant difference in relative survival. However, we
saw a trend toward increased disease-specific mortality after
;8 to 10 years, probably indicating vein graft degeneration
or worsening coronary artery disease (16). The number of
patients operated on with concomitant CABG increased
during recent years. Hence, with prolonged follow-up,
concomitant ischemic heart disease may prove to be a
relative risk factor in this study group.
Table 4. Basic Data Concerning Observed and Expected Deaths Based on Data From Follow-Up Years 1 through 15*
Patient-
Years at
Risk
Observed
Number of
Deaths
Expected
Number of
Deaths
O/E
Deaths
O/E
Deaths
Relative to
Baseline
Category
Follow-up year
1 2,227 98 51.9 1.9 1.0
2 2,044.5 69 51.6 1.3 0.7
3 1,814 55 48.4 1.1 0.6
4 1,582.5 50 44.3 1.1 0.6
5 1,348 59 38.8 1.5 0.8
6 1,144 51 33.4 1.5 0.8
7 970.5 39 29.8 1.3 0.7
8 825.5 47 26.2 1.8 1.0
9 683.5 40 22.5 1.8 0.9
10 529.5 32 17.6 1.8 1.0
11 391 28 13.0 2.2 1.1
12 290 17 10.0 1.7 0.9
13 217.5 20 8.0 2.5 1.3
14 144 7 5.3 1.3 0.7
15 83.5 3 3.2 0.9 0.5
NYHA functional class
II 1,954.5 36 32.9 1.1 1.0
IIIA 6,134.5 240 163.2 1.5 1.3
IIIB/IV 6,206 339 208.0 1.6 1.5
Type of valve lesion
AVS/combination† 11,079 472 349.9 1.4 1.0
Regurgitation 3,216 143 54.1 2.6 2.0
Concomitant CABG
No 9,452 353 230.3 1.5 1.0
Yes 4,843 262 173.8 1.5 1.0
AF
No 13,158 517 364.0 1.4 1.0
Yes 1,137 98 40.1 2.4 1.7
Age (yrs)
#50 2,182 31 6.8 4.5 1.0
51–60 2,954.5 98 36.9 2.7 0.6
61–70 5,578.5 274 152.1 1.8 0.4
$71 3,579 212 208.2 1.0 0.2
*Deaths within 30 days of the operation are excluded. †Aortic valve stenosis or combined stenotic and regurgitant lesion.
O/E 5 observed deaths/expected deaths; other abbreviations as in Table 2.
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Patients in preoperative NYHA functional class IIIB or
IV had a significantly higher operative mortality and worse
postoperative observed and relative survival in comparison
with those in class I or II. In contrast, patients with minimal
or no symptoms (class I or II) had low operative mortality
and excellent long-term survival not different from the
expected survival. However, AVR should not be considered
curative in these patients. The optimal timing of such
replacement is a difficult decision that cannot be based solely
on relative survival analyses. To be able to recommend the
operation to each individual patient at the optimal point in
the natural course of aortic valve disease, a number of
considerations must be taken into account. Despite excellent
relative survival, the valve prosthesis introduces the patient
to a new disease process in which complications include
thromboembolism, anticoagulant-related bleeding, infective
endocarditis and structural deterioration of the valve.
Statistical considerations. Our multivariate analyses were
based on an essentially multiplicative Poisson model, which
means that the excess mortality is obtained by modeling of
the ratio of the observed to the expected risk of death. The
regression model most closely connected with relative sur-
vival, as used in the descriptive analyses, is the mixed
additive-multiplicative model that was previously used by
our group (17–20). Here the excess (disease-specific) mor-
tality is modeled additively as the difference between the
observed death hazard and the hazard expected in the
comparison group from the general population. In cases
where the excess mortality defined in this way is very small,
the mixed additive-multiplicative model becomes doubtful.
A more detailed discussion of the models can be found in
the Statistical Appendix.
Study limitations. Several factors must be taken into
account when the relative survival function (4,21–23) is used
to measure the outcome. First, in calculations of the
expected survival in the study group, it is assumed that the
survival in the general population is unaffected by deaths
related to the disease being studied. Because deaths from
heart valve disease are uncommon among younger people in
the general population, the relative survival rates calculated
in this study should reflect the disease-specific death risk, at
least in the younger age groups. However, with increasing
age, the prevalence rates of heart valve disease (24) and
coronary artery disease in the general population increase,
and these constitute a common cause of death. Second,
patients accepted for heart valve surgery are selected with
respect to their better overall medical condition concerning
noncardiac diseases at the time of operation. This is prob-
ably more pronounced in the older age groups and will
partly explain their high relative survival rate. Furthermore,
the present study is focused on the prognosis in patients
surviving the immediate postoperative period. Exclusion of
deaths within the first month also biases the results in favor
of operation. If deaths within the first 30 days postopera-
tively in, for example, the highest age group were considered
(n 5 56), the number of deaths in this category during the
15 years of follow-up would be 268, as compared with the
208.2 expected in that age group. In the youngest age group,
the observed number of deaths would increase by another
30% if operative deaths were considered.
It is a limitation of our study that left ventricular function,
a major predictor of long-term survival after AVR (1,25),
was not considered. However, data on NYHA functional
class and preoperative AF were available in all patients and
may at least theoretically reflect different aspects of left
ventricular performance.
Conclusions. This study emphasizes the impact of age on
all of the risk factors we studied. The patients showed an
excess mortality during the entire follow-up period. Three
characteristics on study inclusion—namely, advanced
NYHA functional class, AF and pure aortic regurgitation—
were independent risk factors, whereas older age was not.
Studies of relative survival provide information supplemen-
tary to the estimation of the benefits in different age groups.
STATISTICAL APPENDIX
In an analysis based on relative survival, a formal model
must be chosen. It is not self-evident which model should
be used, and several alternatives are available. The relative
survival (RS) in a group with a death risk of P1 is obviously
RS 5 (1 2 P1/(1 2 P0), if the corresponding risk in the
general population is P0. The relative survival is approxi-
Table 5. Fully Multivariate Model Based on Relative Death
Risks (Deaths Within 30 Days After Aortic Valve Replacement
Excluded) and Considering Other Variables
O/E Deaths
Relative to
Baseline
Category
95%
Confidence
Interval
NYHA functional class
I/II 1.0 Reference
IIIA 1.6 1.1–2.3
IIIB/IV 2.0 1.4–2.9
Type of valve lesion
AVS/combination* 1.0 Reference
Regurgitation 1.5 1.3–1.9
Concomitant CABG
No 1.0 Reference
Yes 1.2 1.0–1.4
AF
No 1.0 Reference
Yes 1.8 1.4–2.2
Age (yrs)
#50 1.0 Reference
51–60 0.6 0.4–0.8
61–70 0.4 0.3–0.5
$71 0.2 0.1–0.3
*Aortic valve stenosis or combined stenotic and regurgitant lesion.
O/E 5 observed/expected; other abbreviations as in Table 2.
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mately equal to 1 2 (P1 2 P0) for low P0 and P1. Thus, the
basically additive model is closely connected with the
concept of relative survival, which supports the use of this
type of model when the basic descriptive results are pre-
sented in the form of relative survival.
However, in cases where the excess (disease-specific)
mortality is very small, the mixed additive-multiplicative
model becomes doubtful. Therefore, in the present study,
the multiplicative model based on the Poisson distribution
was used for multivariate analysis of relative survival. This
model is formulated basically in terms of the ratio P1/P0 and
compares the observed number of deaths (or the observed
death risk) with the expected number of deaths (or the
general death risk). The results of this analysis can some-
times look completely different from those based on relative
survival, even though the qualitative conclusions are often
the same. The use of the multiplicative model is the reason
for the discrepancy between the age effect on relative
survival depicted in Figure 4 and the relative hazards
obtained in the multivariate analysis.
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